• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The imitator of immune-tolerant chronic hepatitis B: A killer in disguise.

作者信息

Hur Moon Haeng, Lee Jeong-Hoon

机构信息

Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.

出版信息

Clin Mol Hepatol. 2023 Apr;29(2):363-366. doi: 10.3350/cmh.2023.0079. Epub 2023 Mar 9.

DOI:10.3350/cmh.2023.0079
PMID:36907572
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10121298/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a57/10121298/041344a3a2e0/cmh-2023-0079f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a57/10121298/041344a3a2e0/cmh-2023-0079f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a57/10121298/041344a3a2e0/cmh-2023-0079f1.jpg

相似文献

1
The imitator of immune-tolerant chronic hepatitis B: A killer in disguise.免疫耐受型慢性乙型肝炎的模仿者：一个伪装的杀手。
Clin Mol Hepatol. 2023 Apr;29(2):363-366. doi: 10.3350/cmh.2023.0079. Epub 2023 Mar 9.
2
Letter regarding "Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?".关于“肝活检对于确定慢性乙型肝炎免疫耐受期是否必不可少？”的信函
Clin Mol Hepatol. 2023 Jul;29(3):812. doi: 10.3350/cmh.2023.0132. Epub 2023 May 8.
3
Correspondence on Letter regarding "Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?".关于“肝活检对于识别慢性乙型肝炎免疫耐受期是否必不可少？”的信件往来
Clin Mol Hepatol. 2023 Jul;29(3):820. doi: 10.3350/cmh.2023.0135. Epub 2023 May 19.
4
Letter regarding "Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase".关于“慢性乙型肝炎血清免疫耐受期的长期预后及组织学评估的必要性”的信函
Clin Mol Hepatol. 2023 Apr;29(2):510-512. doi: 10.3350/cmh.2023.0018. Epub 2023 Jan 30.
5
Correspondence on Letter regarding "Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune tolerant phase".关于“血清学免疫耐受期慢性乙型肝炎的长期预后及组织学评估需求”信件的通信
Clin Mol Hepatol. 2023 Apr;29(2):513-515. doi: 10.3350/cmh.2023.0044. Epub 2023 Feb 15.
6
Unresolved issues of immune tolerance in chronic hepatitis B.慢性乙型肝炎免疫耐受未解决的问题。
J Gastroenterol. 2020 Apr;55(4):383-389. doi: 10.1007/s00535-020-01665-z. Epub 2020 Feb 3.
7
Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase.慢性乙型肝炎血清学免疫耐受期的长期预后和组织学评估的必要性。
Clin Mol Hepatol. 2023 Apr;29(2):482-495. doi: 10.3350/cmh.2022.0322. Epub 2023 Jan 5.
8
Activated natural killer cells accelerate liver damage in patients with chronic hepatitis B virus infection.活化的自然杀伤细胞会加速慢性乙型肝炎病毒感染患者的肝损伤。
Clin Exp Immunol. 2015 Jun;180(3):499-508. doi: 10.1111/cei.12597. Epub 2015 Apr 12.
9
Prognosis of immune-tolerant phase chronic hepatitis B.免疫耐受期慢性乙型肝炎的预后
Gut. 2018 May;67(5):988. doi: 10.1136/gutjnl-2017-315603. Epub 2017 Nov 25.
10
HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant.慢性乙型肝炎免疫耐受期患者的HBV DNA整合与克隆性肝细胞扩增
Gastroenterology. 2016 Nov;151(5):986-998.e4. doi: 10.1053/j.gastro.2016.07.012. Epub 2016 Jul 22.

引用本文的文献

1
Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study.肝外恶性肿瘤与慢性乙型肝炎抗病毒药物治疗：一项全国性队列研究。
Clin Mol Hepatol. 2024 Jul;30(3):500-514. doi: 10.3350/cmh.2024.0055. Epub 2024 May 10.
2
Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma.治疗慢性乙型肝炎是弥漫性大 B 细胞淋巴瘤的良好预后因素。
Clin Mol Hepatol. 2023 Jul;29(3):794-809. doi: 10.3350/cmh.2023.0057. Epub 2023 May 17.

本文引用的文献

1
Hepatocellular Carcinoma in Korea: an Analysis of the 2015 Korean Nationwide Cancer Registry.韩国的肝细胞癌：对2015年韩国全国癌症登记处数据的分析
J Liver Cancer. 2021 Mar;21(1):58-68. doi: 10.17998/jlc.21.1.58. Epub 2021 Mar 31.
2
Comparable outcomes between immune-tolerant and active phases in noncirrhotic chronic hepatitis B: a meta-analysis.非肝硬化慢性乙型肝炎免疫耐受期和活动期之间可比的结局：一项荟萃分析。
Hepatol Commun. 2023 Jan 18;7(2):e0011. doi: 10.1097/HC9.0000000000000011. eCollection 2023 Feb 1.
3
Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase.
慢性乙型肝炎血清学免疫耐受期的长期预后和组织学评估的必要性。
Clin Mol Hepatol. 2023 Apr;29(2):482-495. doi: 10.3350/cmh.2022.0322. Epub 2023 Jan 5.
4
Association of Chronic Hepatitis B Infection and Antiviral Treatment With the Development of the Extrahepatic Malignancies: A Nationwide Cohort Study.慢性乙型肝炎感染和抗病毒治疗与肝外恶性肿瘤发展的相关性：一项全国性队列研究。
J Clin Oncol. 2022 Oct 10;40(29):3394-3405. doi: 10.1200/JCO.21.01285. Epub 2022 May 13.
5
KASL clinical practice guidelines for management of chronic hepatitis B.《慢性乙型肝炎管理的KASL临床实践指南》
Clin Mol Hepatol. 2022 Apr;28(2):276-331. doi: 10.3350/cmh.2022.0084. Epub 2022 Apr 1.
6
Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B.从富马酸替诺福韦二吡呋酯转换为替诺福韦艾拉酚胺对乙型肝炎患者血脂谱的影响。
PLoS One. 2022 Jan 20;17(1):e0261760. doi: 10.1371/journal.pone.0261760. eCollection 2022.
7
Hepatitis B Virus DNA Integration: In Vitro Models for Investigating Viral Pathogenesis and Persistence.乙型肝炎病毒 DNA 整合：用于研究病毒发病机制和持续性的体外模型。
Viruses. 2021 Jan 26;13(2):180. doi: 10.3390/v13020180.
8
Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B.对于慢性乙型肝炎患者，生物标志物定义的免疫耐受期发生肝细胞癌的风险可忽略不计。
Clin Mol Hepatol. 2021 Apr;27(2):295-304. doi: 10.3350/cmh.2020.0216. Epub 2020 Dec 3.
9
Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients.中等水平的血清乙型肝炎病毒 DNA 与慢性乙型肝炎患者肝细胞癌的风险最高相关。
Aliment Pharmacol Ther. 2020 Jun;51(11):1169-1179. doi: 10.1111/apt.15725. Epub 2020 Apr 14.
10
Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients.鉴定出导致慢性乙型肝炎患者对替诺福韦产生耐药性的四重突变。
J Hepatol. 2019 Jun;70(6):1093-1102. doi: 10.1016/j.jhep.2019.02.006. Epub 2019 Feb 20.